Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers with adenocarcinoma being the most common subtype. Patients with stage IV NSCLC typically have poor prognosis. In these patients, identification of actionable genomic alterations allows for the selection of targeted th...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2026-01-01
|
| Col·lecció: | Current Oncology |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1718-7729/33/1/55 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|